The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation

Chest

Volumn 128, Issue 5, 2005, Pages 3261-3268

  Myers, Janet N ^a   O'Neil, Kevin M ^b   Walsh, Thomas E ^c   Hoffmeister, Karen J ^b   Venzon, David J ^d   Johnson, Bruce E ^e  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Montgomery County Department of Health   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Lung cancer; Oncology; Pulmonary function test; Radiology; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON MONOXIDE; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADULT; AGED; ARTERIAL GAS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COUGHING; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGIST; RETROSPECTIVE STUDY; REVIEW; SPUTUM; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 28144447584     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.5.3261     Document Type: Article

References (28)

1. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer: Lung Cancer Working Cadre. J Natl Cancer Inst 1997; 89:1782-1788
2. Lewinski T, Zulawski M. Small cell lung cancer survival: 3 years as a minimum for predicting a favorable outcome. Lung Cancer 2003; 40:203-213
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379-392
4. Pignon JP, Arriagada R. Role of thoracic radiotherapy in limited-stage small-cell lung cancer: quantitative review based on the literature versus meta-analysis based on individual data. J Clin Oncol 1992; 10:1819-1820
5. Marks LB, Yu X, Vujaskovic Z, et al. Radiation-induced lung injury. Semin Radiat Oncol 2003; 13:333-345
6. Lund MB, Kongerud J, Nome O, et al. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 1995; 6:495-501
7. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912-918
8. Movsas B, Raffin TA, Epstein AH, et al. Pulmonary radiation injury. Chest 1997; 111:1061-1076
9. Choi NC, Kanarek DJ. Toxicity of thoracic radiotherapy on pulmonary function in lung cancer. Lung Cancer 1994; 10(suppl):S219-S230
10. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215
11. Adjei AA, Marks RS, Bonner JA. Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 1999; 74:809-816
12. Johnson BE, Hide DC, Bunn PA, et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation: data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med 1985; 103:430-438
13. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987; 106:655-662
14. Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14:806-813
15. Catane R, Lichter A, Lee YJ, et al. Small cell lung cancer: analysis of treatment factors contributing to prolonged survival. Cancer 1981; 48:1936-1943
16. McDonald S, Rubin P, Phillips TL, et al. Injury to the lung from cancer therapy: clinical syndromes, measurable end-points, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995; 31:1187-1203
17. Johnson BE, Linnoila RI, Williams JP, et al. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol 1995; 13:101-111
18. Miller KL, Zhou SM, Barrier RC Jr, et al. Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2003; 56:611-615
19. Vaaler AK, Forrester JM, Lesar M, et al. Obstructive atelectasis in patients with small cell lung cancer: incidence and response to treatment. Chest 1997; 111:115-120
20. Maas KW, van der Lee I, Bolt K, et al. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 2003; 41:345-351
21. Abratt RP. Long-term changes in pulmonary function tests after definitive irradiation for lung cancer. Int J Radiat Oncol Biol Phys 2004; 58:1008
22. Brooks BJ Jr, Seifter EJ, Walsh TE, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 1986; 4:200-209
23. Villani F, De Maria P, Bonfante V, et al. Late pulmonary toxicity after treatment for Hodgkin's disease. Anticancer Res 1997; 17:4739-4742
24. Hassink EA, Souren TS, Boersma LJ, et al. Pulmonary morbidity 10-18 years after irradiation for Hodgkin's disease. Eur J Cancer 1993; 29:343-347
25. Ohe Y. Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer. Panminerva Med 2002; 44:205-212
26. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003; 67:275-283
27. Segawa Y, Takigawa N, Kataoka M, et al. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1997; 39:91-98
28. Solomon B, Ball DL, Richardson G, et al. Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer 2003; 41:353-361